Voya Investment Management LLC Sells 4,534 Shares of Arbutus Biopharma Corporation $ABUS

Voya Investment Management LLC trimmed its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 9.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,523 shares of the biopharmaceutical company’s stock after selling 4,534 shares during the period. Voya Investment Management LLC’s holdings in Arbutus Biopharma were worth $145,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ABUS. Cyndeo Wealth Partners LLC bought a new stake in shares of Arbutus Biopharma during the first quarter worth approximately $35,000. Ameriprise Financial Inc. bought a new stake in shares of Arbutus Biopharma during the fourth quarter worth approximately $62,000. EntryPoint Capital LLC bought a new stake in shares of Arbutus Biopharma during the first quarter worth approximately $65,000. XTX Topco Ltd raised its stake in shares of Arbutus Biopharma by 37.7% during the first quarter. XTX Topco Ltd now owns 72,412 shares of the biopharmaceutical company’s stock worth $253,000 after buying an additional 19,831 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Arbutus Biopharma by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 76,031 shares of the biopharmaceutical company’s stock valued at $265,000 after purchasing an additional 6,371 shares in the last quarter. 43.79% of the stock is owned by institutional investors.

Arbutus Biopharma Stock Up 1.8%

Shares of ABUS stock opened at $4.54 on Wednesday. The firm has a fifty day moving average of $3.82 and a 200-day moving average of $3.48. Arbutus Biopharma Corporation has a 12-month low of $2.70 and a 12-month high of $5.10. The company has a market capitalization of $870.31 million, a price-to-earnings ratio of -15.66 and a beta of 1.01.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. Arbutus Biopharma had a negative net margin of 352.24% and a negative return on equity of 59.28%. The company had revenue of $10.74 million during the quarter, compared to the consensus estimate of $2.21 million. On average, equities analysts expect that Arbutus Biopharma Corporation will post -0.39 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ABUS shares. Chardan Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Monday, August 11th. Wall Street Zen downgraded shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $5.00.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.